Menu Search
Equities

Shanghai Rendu Biotechnology Co Ltd

688193:SHH

Shanghai Rendu Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)41.87
  • Today's Change-3.13 / -6.96%
  • Shares traded794.31k
  • 1 Year change-13.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Rendu Biotechnology Co Ltd's revenues fell -45.89% from 303.85m to 164.41m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 23.33m to 8.26m, a -64.60% decrease.
Gross margin79.87%
Net profit margin11.95%
Operating margin11.74%
Return on assets2.07%
Return on equity2.26%
Return on investment2.22%
More ▼

Cash flow in CNYView more

In 2023, Shanghai Rendu Biotechnology Co Ltd increased its cash reserves by 104.02%, or 310.63m. Cash Flow from Investing totalled 301.92m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 17.19m in cash from operations while cash used for financing totalled 8.97m.
Cash flow per share--
Price/Cash flow per share--
Book value per share23.18
Tangible book value per share23.17
More ▼

Balance sheet in CNYView more

Shanghai Rendu Biotechnology Co Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 609.27m.
Current ratio12.37
Quick ratio12.02
Total debt/total equity0.0052
Total debt/total capital0.0052
More ▼

Growth rates in CNY

Year on year, growth in dividends per share increased 60.00% while earnings per share excluding extraordinary items fell by -64.60%. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)36.85%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		342.67
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.